试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-24
Pre-operative Enoxaparin in the Surgical Management of Multi-trauma Patients Undergoing Orthopedic Surgical Procedures
编号:NCT05081375登记状态:提前终止企业 / 申办者:Valleywise Health
药物 / 成分:Enoxaparin Injectable Product、Sodium chloride
登记的停止原因(原文):PI left the institution
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-24
A Trial to Determine the Efficacy and Safety of Presendin in IIH
编号:NCT05347147登记状态:提前终止企业 / 申办者:Invex Therapeutics Ltd.
药物 / 成分:Presendin、Placebo
登记的停止原因(原文):Following a strategic evaluation of its IIH EVOLVE Phase III clinical trial investigating Presendin™, the Invex Board has made the difficult decision that the continuation of the trial is not viable and therefore the trial has been terminated.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-24
Randomized Trial Comparing Irrisept to Saline Irrigation for Infection Prevention
编号:NCT05402995登记状态:提前终止企业 / 申办者:Brett D. Crist
药物 / 成分:Irrisept (Irrigation Solution)、Saline
登记的停止原因(原文):Enrollment was not progressing as expected.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-24
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
编号:NCT05490563登记状态:提前终止企业 / 申办者:Seelos Therapeutics, Inc.
药物 / 成分:SLS-005、Placebo
登记的停止原因(原文):This was a business decision due to financial considerations, not based on data related to safety or therapeutic effects.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-24
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
编号:NCT05538624登记状态:提前终止企业 / 申办者:Avenge Bio, Inc
药物 / 成分:AVB-001 (Dose Escalation Phase)、AVB-001 (Dose Expansion Phase)
登记的停止原因(原文):Sponsor Decision to close study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-24
IMM60 and Pembrolizumab in Melanoma and NSCLC
编号:NCT05709821登记状态:提前终止企业 / 申办者:iOx Therapeutics
药物 / 成分:IMM60、Pembrolizumab
登记的停止原因(原文):Prioritization of other pipeline assets. No safety or efficacy issues were observed.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-23
Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg
编号:NCT00647972登记状态:提前终止企业 / 申办者:Mylan Pharmaceuticals Inc
药物 / 成分:Olanzapine Tablets 20 mg、Zyprexa® Tablets 20 mg
登记的停止原因(原文):during Period 1 due to numerous orthostatic AEs that occurred. Subsequently, RLD was reduced to 5 mg due to safety concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-23
Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr
编号:NCT00648414登记状态:提前终止企业 / 申办者:Mylan Pharmaceuticals Inc
药物 / 成分:Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1、Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2、Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3、Duragesic 25 mcg/h + Clinical Procedure 1
登记的停止原因(原文):due to multiple subjects reporting pain and burning at the phlebotomy sites after 38hr
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-23
WAVECREST Post Market Clinical Follow-Up (PMCF) Study
编号:NCT03204695登记状态:提前终止企业 / 申办者:Coherex Medical
药物 / 成分:Percutaneous LAA Closure、Anticoagulation or Clopidogrel
登记的停止原因(原文):Study closed due to device design modifications.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-23
Liver Transplantation With Tregs at UCSF
编号:NCT03654040登记状态:提前终止企业 / 申办者:National Institute of Allergy and Infectious Diseases (NIAID)
药物 / 成分:arTreg、leukapheresis、cyclophosphamide、mesna
登记的停止原因(原文):The study was terminated by the Sponsor prior to any participants receiving the investigational product.
查看官方原始记录 ↗